Why Tandem Diabetes Care (TNDM) Stock Dropped After Its Latest Update

Tandem Diabetes Care (TNDM) just released third quarter 2026 results. The company reported sales of US$283.69 million and a net loss of US$7.09 million, drawing fresh attention to the stock.

The latest quarterly update has landed in the middle of a choppy year for Tandem Diabetes Care, with the share price falling 5.56% on the day and 9.10% over the past week. Despite this, the shares still show an 11.32% 1 month share price return and a 34.96% 1 year total shareholder return, which indicates that long term holders have seen gains even as recent momentum has faded.

Scan beyond Tandem Diabetes Care to see how it stacks up against other hand picked healthcare names with resilient balance sheets in our list of solid balance sheet and fundamentals (25 results).

Tandem Diabetes Care has just given long term holders a strong 1 year gain, even after this week’s pullback. Has most of that upside already played out, or does the valuation still leave room on the table?

Most Popular Narrative: 35% Undervalued

At a last close of $17.99 against a narrative fair value of $27.76, Tandem Diabetes Care trades at a steep discount that puts the focus squarely on whether the margin story can keep progressing.

Structural margin improvement efforts are gaining traction as gross margin has reached the mid to high 50% range, adjusted EBITDA margins have turned positive for four consecutive quarters, and operating expenses and stock based compensation are being held in check. Together, these factors can support higher net margins and stronger earnings power if revenue continues to scale.

See why 8 investors see Tandem Diabetes Care as 35% undervalued.

Result: Fair Value of $27.76 (UNDERVALUED)

Still, the narrative around Tandem Diabetes Care hinges on supply disruptions easing and the t:slim app recall not causing a longer hit to pump starts and upgrades.

Find out about the key risks to this Tandem Diabetes Care narrative.

Next Steps

Does the Tandem Diabetes Care story look upbeat or still unproven to you right now? Act quickly, stress test the assumptions, and then weigh those 3 key rewards.

Hunting for your next investment idea after Tandem Diabetes Care?

Do not stop with Tandem Diabetes Care. Broaden your watchlist now and use focused screeners to surface stocks that match your risk, income, and value preferences.

• Target resilient balance sheets by reviewing companies in the list of solid balance sheet and fundamentals (25 results) that pair manageable debt with dependable fundamentals.
• Zero in on mispriced opportunities by checking the 42 high quality undervalued stocks that highlight stocks trading below their assessed worth on quality metrics.
• Build a steadier income stream by scanning the 6 dividend fortresses that feature higher yielding businesses focused on consistent shareholder payouts.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com